Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller to Board of Directors

On May 27, 2026, Alto Neuroscience, Inc. announced the appointment of Andrew Miller, Ph.D., to its Board of Directors as a Class III director, with a term expiring at the 2027 Annual Meeting of Stockholders. Dr. Miller fills a vacancy created by the Board's expansion from six to seven members. He has also been appointed to the Nominating and Corporate Governance Committee, replacing Christopher Nixon Cox. Dr. Miller brings significant industry experience, having founded Karuna Therapeutics and served as its President of R&D until its acquisition by Bristol Myers Squibb. Under the Company’s Non-Employee Director Compensation Policy, Dr. Miller will receive an initial stock option grant valued up to $400,000, an annual cash retainer of $40,000 for board service, and an additional $5,000 for committee service. The Board has confirmed Dr. Miller’s status as an independent director under NYSE and SEC regulations.